Breathe Well Live Well
Business Wire (press release) |
3 out of 4 people with symptomatic asthma report reduced productivity at work
Business Wire (press release) Results were released today by Boehringer Ingelheim from an international survey, providing new insight into the negative impact of persistent asthma symptoms on people's work productivity and their ability to perform everyday activities. The Work … |
View full post on asthma – Google News
MD Magazine |
COPD and Asthma Symptomatic Overlap
MD Magazine Smokers and nonsmokers with chronic asthma share symptoms of chronic obstructive pulmonary disease (COPD), likely due to small airway remodeling, suggest findings published in the journal Chest. The concurrent disease is often referred to as asthma … |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: Vapendavir; Drug: Vapendavir; Drug: Placebo
Sponsor: Biota Pharmaceuticals, Inc.
Recruiting – verified February 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: Respimat® Budesonide low dose; Drug: Respimat® Budesonide high dose; Drug: Turbohaler® Budesonide; Drug: Placebo
Sponsor: Boehringer Ingelheim
Completed – verified July 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Phase III Study: Tiotropium Effective In Symptomatic Asthma Patients – Science 2.0
Science 2.0 Tiotropium delivered by the Respimat(R) Soft Mist(TM) Inhaler (SMI) increases time to first severe exacerbation and first episode of asthma worsening across a broad spectrum of patients who remain symptomatic despite at least inhaled corticosteroids … Phase III results: tiotropium(*) Respimat(R) effective in symptomatic asthma … Boehringer Ingelheim Presents Phase 3 Sub-Analyses for Tiotropium Across a … |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: Placebo; Drug: JNJ-38518168
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Not yet recruiting – verified March 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Phase III results: tiotropium* Respimat® is effective in symptomatic asthma …
Business Wire (press release) SAN ANTONIO, Texas–(BUSINESS WIRE)–Tiotropium delivered once daily via Respimat™ significantly improved lung function and reduced asthma exacerbations in patients who remain symptomatic despite treatment with at least ICS†/LABA‡, irrespective … Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic … |
View full post on asthma – Google News
|
Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic …
PR Newswire (press release) SAN ANTONIO, Feb. 23, 2013 /PRNewswire/ — Boehringer Ingelheim presented today a new subset of data from the Phase III UniTinA-asthma™ program at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San … |
View full post on asthma – Google News
|
GSK ills symptomatic of wider malaise
Financial Times The US Food and Drug Administration in 2000 authorised Advair, which combines two drugs and is breathed in with an inhaler, for long-term maintenance treatment of asthma, not for those with mild intermittent attacks. Yet the US court filings cite … |
View full post on asthma – Google News
Condition: Rhinovirus
Interventions: Drug: BTA798; Drug: Placebo
Sponsor: Biota Scientific Management Pty Ltd
Recruiting – verified September 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days